Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Activated plasma thromboplastin component VII for treating massive haemorrhage caused by thrombolysis therapy

A technology of blood coagulation factor and therapy, which is applied in the field of treating massive bleeding caused by thrombolytic therapy with activated blood coagulation factor VII, and can solve problems such as bleeding complications, hemorrhagic shock, etc.

Inactive Publication Date: 2008-08-06
BOEHRINGER INGELHEIM PHARM KG
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The combined use of these agents, although very effective therapeutically, still carries a significant risk of bleeding complications including hemorrhagic shock (refs 2, 3)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Activated plasma thromboplastin component VII for treating massive haemorrhage caused by thrombolysis therapy
  • Activated plasma thromboplastin component VII for treating massive haemorrhage caused by thrombolysis therapy
  • Activated plasma thromboplastin component VII for treating massive haemorrhage caused by thrombolysis therapy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0025] Example: Effect of Factor VIIa on Hemorrhage Induced by Standard Thrombolytic Treatment in Rats reverse effect

[0026] method

[0027] animal : Rat Chbb Thom male female, 200-300g

[0028] anaesthetization : Narcoren 60mg / kg (intraperitoneal injection) + continuous infusion of 0.6ml / h (intraperitoneal injection) (Narcoren + normal saline, ratio 1:5)

[0029] compound :

[0030] Recombinant tissue plasminogen activator (rt-PA)

[0031] Usage of rt-PA: 100nM / kg, intravenous administration:

[0032] 10% intravenous injection: 10nM / kg (1ml / kg)

[0033] 90% intravenous infusion: 90nM / kg / hour (3ml / kg / h)

[0034] Heparin / Ratiopharm :

[0035] Heparin usage:

[0036] 50U / kg intravenous injection together with rt-PA

[0037] +Infusion: 40U / kg / h

[0038] ASA = acetylsalicylic acid:

[0039] 30mg / kg intravenous injection together with rt-PA

[0040] Coagulation factor VIIa (hereinafter referred to as: Novoseven):

[0041] Dose: 1mg / kg (Vol.1.667ml / kg) ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a method for treating massive hemorrhage resulted from thrombolytic therapy / fibrinolytic therapy through administrating an active coagulation factor VII (VIIa) and functional derivatives thereof with an effective amount to the volunteers. The massive hemorrhage includes intracranial hemorrhage.

Description

Background technique [0001] The hemostatic system, including platelets, coagulation, and fibrinolysis, plays a vital role in maintaining blood flow and limiting blood loss during vascular injury. When a blood vessel is damaged, platelets adhere to the vessel wall, aggregate and form a plug, which is solidified by a fibrin network that is activated by coagulation factor VII when blood coagulation is activated, Formed by the activation of coagulation factor X and prothrombin. After blood loss stops, wound healing begins, after which the fibrinolytic system dissipates the clot through tissue plasminogen activator (t-PA)-induced production of plasmin. [0002] In pathological conditions, as in cardiovascular disease, this system escapes normal physiological regulation, causing complete blockage of the vessel, as is observed after atherosclerotic plaque detachment. Thrombolytic therapy is often used to treat thrombotic blockages and restore blood flow (Reference 1). [0003] Thr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/36A61P7/04
Inventor 科德·斯卡米拉琼·M·史塔生格哈德·休塞尔沃尔夫冈·威南
Owner BOEHRINGER INGELHEIM PHARM KG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com